Biocon has informed that it enclosed Company Statement with respect to ‘Biocon Biologics Launches Nepexto®, a Biosimilar to Enbrel® (Etanercept), in Australia’. The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.